PROX1/α-SMA correlated with colorectal cancer progression, poor outcomes and therapeutic resistance


A new research paper titled “PROX1 interaction with α-SMA-rich cancer-associated fibroblasts facilitates colorectal cancer progression and correlates with poor clinical outcomes and therapeutic resistance” has been published in Aging. The study found that the tumor microenvironment plays a key role in tumor progression, with cancer-associated fibroblasts expressing alpha-smooth muscle actin (α-SMA) correlates with unfavorable outcomes in colorectal cancer (CRC). PROX1, a transcription factor, stands out as it influences CAF dysregulation in CRC and is associated with poor prognosis. The study emphasized the connection between PROX1 and α-SMA in CAFs and suggested the potential development of inhibitors targeting this gene set for therapeutic strategies.

Source link

error: Content is protected !!